Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials

Biglia, Nicoletta; Maffei, Silvia; Lello, Stefano; Nappi, Rossella E.

doi:10.3109/09513590.2010.495437

Cited by 60 publications

(34 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, the included studies did not particularly focus on tibolone therapy-related side effects. One should notice that the side effects after tibolone therapy with doses 2.5 mg/day are uncommon [63]. In the Long-Term Intervention on Fractures with Tibolone (LIFT) trial [64] in older postmenopausal women (aged 60e85 years) tibolone therapy (in comparison to placebo) significantly reduced the risk of vertebral and nonvertebral fractures, invasive breast cancer and colon cancer, however, increased of the stroke risk.…”

Section: Discussionmentioning

confidence: 97%

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…When we stratified opposed estrogens by progestogen component, only norethisterone acetate and estrogen, and medroxyprogesterone acetate and estrogen were associated with a decreased OR for incident gout. Tibolone-a synthetic steroid hormone acting as a selective tissue estrogenic activity regulator acting as an estrogen receptor agonist 34 whose metabolites have estrogenic, androgenic, and progestogenic properties 35 -was also associated with a decreased OR for gout. The effect of tibolone might be explained by its progestogenic component.…”

Section: Discussionmentioning

confidence: 99%

Association of hormone therapy and incident gout

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It has positive effects on controlling climacteric symptoms, prevents bone loss as evident on serial bone densitometry, and exerts a beneficial androgenic effect on mood and libido. [10][11][12] Additionally, it has the advantage of zero stimulation of endometrium and breast tissue. Moreover, studies suggest that tibolone potentially confers benefits on cognitive performance too.…”

Section: Resultsmentioning

confidence: 99%

Hormone Replacement Therapy for Surgical Menopause: Is there an Ideal Drug? A Comparative Study of Conjugated Equine Estrogens and Tibolone

2017

Journal of SAFOMS

View full text Add to dashboard Cite

Objective: To compare the effects of continuous combined conjugated equine estrogens (CEE) with those of tibolone on symptom control, lipid profile, and tolerability in women with surgical menopause. Materials and methods:This was a randomized controlled trial study conducted in the Department of Obstetrics and Gynaecology of Global Rainbow Hospital Pvt. Ltd., Agra (2014-2016) comprising 150 women. Generally, healthy postmenopausal women having undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy irrespective of age and indication of surgery and no absolute contraindications to hormone replacement therapy (HRT) or tibolone were enrolled. Fifty subjects did not receive any HRT, 50 were treated with CEE 0.625 mg, and 50 were given tibolone 2.5 mg for 13 treatment cycles, each of 28 days. Results were statistically analyzed regarding drug efficacy in amelioration of menopausal symptoms and side effects at follow-up periods of 1, 6, and 12 months.Results: A total of 150 subjects were enrolled and received at least one dose of the study medication, of which 134 (89.4%) subjects completed the study (n = 40 in CEE and n = 44 in tibolone). The incidence of postmenopausal symptoms decreased significantly over time in the treatment groups, compared with baseline, including significant decreases in the incidence of urogenital and sexual health symptoms, with p-values 0.001 and 0.004 in cases that received CEE and tibolone respectively.Significant differences in symptom control (other than hot flashes) were observed between treatment groups in a few different cycles for different symptoms, but no consistent or clinically significant trends were observed.Significant decreases in total cholesterol (5.6%) and low-density lipoprotein cholesterol (7.5%) were observed at cycle 13, compared with baseline, in the CEE group, and significant decreases in high-density lipoprotein cholesterol (8.5%) and triglycerides (13.7%) were observed at cycle 13, compared with baseline, in the tibolone group.Significant weight gain was observed at cycle 13 in the tibolone group (3.05 kg), compared with the CEE group (0.96 kg). The incidences of adverse events were similar in both treatment groups. oRIGINaL aRTICLE Associate ProfessorDepartment of Obstetrics and Gynecology, SN Medical College Agra, Uttar Pradesh, India Corresponding Author: Nidhi Gupta, Associate Professor Department of Obstetrics and Gynecology, SN Medical College Agra, Uttar Pradesh, India, e-mail: dr.nidhi-gupta@rediffmail.com 10.5005/jp-journals-10032-1097Conclusion: Women treated with CEE and tibolone showed significant improvement of climacteric symptoms, including urogenital and sexual health symptoms. Treatment with either preparation significantly improved subjective wellbeing, vasomotor symptoms, and vaginal dryness.The CEE and tibolone each induced a different mix of beneficial changes in the lipid profile.It is seen that tibolone seems to be effective on estrogen withdrawal symptoms and with its acceptable androgenic side effects can be an...

show abstract

Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials

Abstract: T is effective in treating menopausal syndrome with a good tolerability profile. In spite of some unsolved issues in term of safety, T is still a good treatment option for early PMW.

Cited by 60 publications

References 93 publications

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

Association of hormone therapy and incident gout

Hormone Replacement Therapy for Surgical Menopause: Is there an Ideal Drug? A Comparative Study of Conjugated Equine Estrogens and Tibolone

Contact Info

Product

Resources

About